Melbourne, Australia and St. Gallen, Switzerland - CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY), announced the provisional notice of the end result of its public tender offer to acquire all publicly held shares of Vifor Pharma Ltd. (SIX:VIFN; ISIN:CH0364749348) for USD 179.25 per share as indicated in the offer prospectus of 18 January 2022.

According to the provisional end result, taking into account the Vifor Pharma shares held by the offeror and the persons acting in concert with the offeror at the end of the additional acceptance period and the Vifor Pharma shares tendered during the main offer period and the additional acceptance period, CSL's participation at the end of the additional acceptance period on 22 March 2022 amounts to a total of 94 percent of all listed Vifor Pharma shares as of 22 March 2022, subject to the completion of the offer. The provisional notice of the end result is available at www.csltransaction.com.

The definitive notice of the end result is expected to be published on 28 March 2022 and will contain statements as to the satisfaction of the offer conditions and as to the settlement of the offer, subject to the satisfaction or waiver of all offer conditions. CSL already waived the 80% acceptance rate condition set forth in the offer prospectus and declared the tender offer successful in the definitive notice of the interim result.

Contact:

Media

Nathalie Ponnier

Global Head Corporate Communications

T: +41 79 957 96 73

E: media@viforpharma.com

About Vifor Pharma Group

Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency and nephrology. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions across iron, dialysis, nephrology and rare conditions. Vifor Pharma Group strives to help patients around the world with severe, chronic and rare diseases lead better, healthier lives. It specializes in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and includes the companies: Vifor Pharma, Sanifit Therapeutics, and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For more information, please visit viforpharma.com

About CSL

CSL (ASX: CSL; USOTC: CSLLY) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL - including our two businesses, CSL Behring and Seqirus- provides life-saving products to more than 100 countries and employs more than 25,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For more information visit csl.com.

Forward-Looking Statements

This announcement may contain statements that constitute forward-looking statements. The words 'anticipate', 'believe', 'expect', 'estimate', 'aim', 'project', 'forecast', 'estimate', 'risk', 'likely', 'intend', 'outlook', 'should', 'could', 'would', 'may', 'will', 'continue', 'plan', 'probability', 'indicative', 'seek', 'target', 'plan' and other similar expressions are intended to identify forward-looking statements.

Any such statements, opinions and estimates in this announcement speak only as of the date hereof and are based on assumptions and contingencies subject to change without notice, as are statements about market and industry trends, projections, guidance and estimates. Forward-looking statements are provided as a general guide only. The forward-looking statements in this announcement are not indications, guarantees or predictions of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of CSL, its officers, employees, agents and advisors, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct, and may cause actual results to differ materially from those expressed or implied in such statements. You are strongly cautioned not to place undue reliance on forward-looking statements.

This announcement is not financial product or investment advice, a recommendation to acquire or sell securities or accounting, legal or tax advice. It does not constitute an invitation or offer to apply for securities. It has been prepared without taking into account the objectives, financial or tax situation or needs of individuals. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial and tax situation and needs and seek legal and taxation advice appropriate for their jurisdiction. CSL is not licensed to provide financial product advice in respect of an investment in securities.

(C) 2022 Electronic News Publishing, source ENP Newswire